• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Sonida Senior Living Inc.

    10/17/24 5:33:31 PM ET
    $SNDA
    Hospital/Nursing Management
    Health Care
    Get the next $SNDA alert in real time by email
    SC 13D/A 1 ff4003040_13da6-conversant.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D
    (RULE 13D - 101)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND
    AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a)
    (Amendment No. 6)*
    Sonida Senior Living, Inc.
    (Name of Issuer)
    Common Stock, $0.01 par value per share
    (Title of Class of Securities)
    140475203
    (CUSIP Number)

    Paul Dumaine
    Conversant Capital LLC
    25 Deforest Avenue
    Summit, NJ 07901
    908-466-5100
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    With a copy to:
    John M. Bibona
    Fried, Frank, Harris, Shriver & Jacobson LLP
    One New York Plaza
    New York, NY 10004
    (212) 859-8000

    October 10, 2024
    (Date of Event which Requires Filing of this Statement)



    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
     
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
     
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    CUSIP NO. 140475203
    1
    NAMES OF REPORTING PERSONS
     
     
    Conversant Dallas Parkway (A) LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    7,753,089(1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    7,753,089(1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    7,753,089(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    35.7%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1) Consists of (i) 5,266,159 shares of Common Stock, (ii) 1,203,308 shares of Common Stock issuable upon conversion of 38,742 shares of Series A Preferred Stock of the Issuer, (iii) 968,538 shares of Common Stock issuable upon exercise of warrants of the Issuer, and (iv) 315,084 shares of Common Stock issuable upon draws by the Issuer under the Conversant Equity Commitment.
    (2) The percentage reflected is based on the sum of (i) 19,070,277 outstanding shares of Common Stock on September 13, 2024, as provided under Form S-3 filed by the Issuer with the Commission on September 27, 2024, plus (ii) 1,281,205 shares of Common Stock issuable in the aggregate upon conversion of the Series A Preferred Stock held by Conversant Dallas Parkway (A) L.P. and Conversant Dallas Parkway (B) LP, plus (iii) 1,031,250 shares of Common Stock issuable in the aggregate upon exercise of the Issuer warrants held by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP, plus (iv) 350,000 shares of Common Stock issuable in the aggregate upon draws of the Issuer under the Conversant Equity Commitment entered into by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP.


    CUSIP NO. 140475203
    1
    NAMES OF REPORTING PERSONS
     
     
    Conversant Dallas Parkway (B) LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    885,269(1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    885,269(1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    885,269(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    4.1%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1) Consists of (i) 709,744 shares of Common Stock, (ii) 77,897 shares of Common Stock issuable upon conversion of 2,508 shares of Series A Preferred Stock of the Issuer, (iii) 62,712 shares of Common Stock issuable upon exercise of warrants of the Issuer, and (iv) 34,916 shares of Common Stock issuable upon draws by the Issuer under the Conversant Equity Commitment.
    (2) The percentage reflected is based on the sum of (i) 19,070,277 outstanding shares of Common Stock on September 13, 2024, as provided under Form S-3 filed by the Issuer with the Commission on September 27, 2024, plus (ii) 1,281,205 shares of Common Stock issuable in the aggregate upon conversion of the Series A Preferred Stock held by Conversant Dallas Parkway (A) L.P. and Conversant Dallas Parkway (B) LP, plus (iii) 1,031,250 shares of Common Stock issuable in the aggregate upon exercise of the Issuer warrants held by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP, plus (iv) 350,000 shares of Common Stock issuable in the aggregate upon draws of the Issuer under the Conversant Equity Commitment entered into by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP.


    CUSIP NO. 140475203
    1
    NAMES OF REPORTING PERSONS
     
     
    Conversant Dallas Parkway (D) LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,032,216(1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,032,216(1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,032,216(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    4.7%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1)  Consists of 1,032,216 shares of Common Stock.
    (2) The percentage reflected is based on the sum of (i) 19,070,277 outstanding shares of Common Stock on September 13, 2024, as provided under Form S-3 filed by the Issuer with the Commission on September 27, 2024, plus (ii) 1,281,205 shares of Common Stock issuable in the aggregate upon conversion of the Series A Preferred Stock held by Conversant Dallas Parkway (A) L.P. and Conversant Dallas Parkway (B) LP, plus (iii) 1,031,250 shares of Common Stock issuable in the aggregate upon exercise of the Issuer warrants held by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP, plus (iv) 350,000 shares of Common Stock issuable in the aggregate upon draws of the Issuer under the Conversant Equity Commitment entered into by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP.


    CUSIP NO. 140475203
    1
    NAMES OF REPORTING PERSONS
     
     
    Conversant Dallas Parkway (F) LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    648,942(1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    648,942(1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    648,942(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    3.0%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1) Consists of 648,942 shares of Common Stock.
    (2) The percentage reflected is based on the sum of (i) 19,070,277 outstanding shares of Common Stock on September 13, 2024, as provided under Form S-3 filed by the Issuer with the Commission on September 27, 2024, plus (ii) 1,281,205 shares of Common Stock issuable in the aggregate upon conversion of the Series A Preferred Stock held by Conversant Dallas Parkway (A) L.P. and Conversant Dallas Parkway (B) LP, plus (iii) 1,031,250 shares of Common Stock issuable in the aggregate upon exercise of the Issuer warrants held by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP, plus (iv) 350,000 shares of Common Stock issuable in the aggregate upon draws of the Issuer under the Conversant Equity Commitment entered into by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP.
     


    CUSIP NO. 140475203
    1
    NAMES OF REPORTING PERSONS
     
     
    Conversant PIF Aggregator A LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,438,263(1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,438,263(1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,438,263(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    6.6%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1) Consists of 1,438,263 shares of Common Stock.
    (2) The percentage reflected is based on the sum of (i) 19,070,277 outstanding shares of Common Stock on September 13, 2024, as provided under Form S-3 filed by the Issuer with the Commission on September 27, 2024, plus (ii) 1,281,205 shares of Common Stock issuable in the aggregate upon conversion of the Series A Preferred Stock held by Conversant Dallas Parkway (A) L.P. and Conversant Dallas Parkway (B) LP, plus (iii) 1,031,250 shares of Common Stock issuable in the aggregate upon exercise of the Issuer warrants held by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP, plus (iv) 350,000 shares of Common Stock issuable in the aggregate upon draws of the Issuer under the Conversant Equity Commitment entered into by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP.
     


    CUSIP NO. 140475203
    1
    NAMES OF REPORTING PERSONS
     
     
    Conversant GP Holdings LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    10,319,516(1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    10,319,516(1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    10,319,516(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    47.5%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1) Consists of (i) 7,657,061 shares of Common Stock, (ii) 1,281,205 shares of Common Stock issuable upon conversion of 41,250 shares of Series A Preferred Stock of the Issuer, (iii) 1,031,250 shares of Common Stock issuable upon exercise of warrants of the Issuer, and (iv) 350,000 shares of Common Stock issuable upon draws by the Issuer under the Conversant Equity Commitment .
    (2) The percentage reflected is based on the sum of (i) 19,070,277 outstanding shares of Common Stock on September 13, 2024, as provided under Form S-3 filed by the Issuer with the Commission on September 27, 2024, plus (ii) 1,281,205 shares of Common Stock issuable in the aggregate upon conversion of the Series A Preferred Stock held by Conversant Dallas Parkway (A) L.P. and Conversant Dallas Parkway (B) LP, plus (iii) 1,031,250 shares of Common Stock issuable in the aggregate upon exercise of the Issuer warrants held by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP, plus (iv) 350,000 shares of Common Stock issuable in the aggregate upon draws of the Issuer under the Conversant Equity Commitment entered into by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP.
     


    CUSIP NO. 140475203
    1
    NAMES OF REPORTING PERSONS
     
     
    Michael J. Simanovsky
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    11,757,779(1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    11,757,779(1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    11,757,779(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    54.1%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    (1) Consists of (i) 9,095,324 shares of Common Stock, (ii) 1,281,205 shares of Common Stock issuable upon conversion of 41,250 shares of Series A Preferred Stock of the Issuer, (iii) 1,031,250 shares of Common Stock issuable upon exercise of warrants of the Issuer, and (iv) 350,000 shares of Common Stock issuable upon draws by the Issuer under the Conversant Equity Commitment.
    (2) The percentage reflected is based on the sum of (i) 19,070,277 outstanding shares of Common Stock on September 13, 2024, as provided under Form S-3 filed by the Issuer with the Commission on September 27, 2024, plus (ii) 1,281,205 shares of Common Stock issuable in the aggregate upon conversion of the Series A Preferred Stock held by Conversant Dallas Parkway (A) L.P. and Conversant Dallas Parkway (B) LP, plus (iii) 1,031,250 shares of Common Stock issuable in the aggregate upon exercise of the Issuer warrants held by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP, plus (iv) 350,000 shares of Common Stock issuable in the aggregate upon draws of the Issuer under the Conversant Equity Commitment entered into by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP.
     


     CUSIP NO. 140475203
    1
    NAMES OF REPORTING PERSONS
     
     
    Conversant Capital LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    11,757,779(1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    11,757,779(1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    11,757,779(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    54.1%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO, IA
     
     
     
     

    (1) Consists of (i) 9,095,324 shares of Common Stock, (ii) 1,281,205 shares of Common Stock issuable upon conversion of 41,250 shares of Series A Preferred Stock of the Issuer, (iii) 1,031,250 shares of Common Stock issuable upon exercise of warrants of the Issuer, and (iv) 350,000 shares of Common Stock issuable upon draws by the Issuer under the Conversant Equity Commitment.
    (2) The percentage reflected is based on the sum of (i) 19,070,277 outstanding shares of Common Stock on September 13, 2024, as provided under Form S-3 filed by the Issuer with the Commission on September 27, 2024, plus (ii) 1,281,205 shares of Common Stock issuable in the aggregate upon conversion of the Series A Preferred Stock held by Conversant Dallas Parkway (A) L.P. and Conversant Dallas Parkway (B) LP, plus (iii) 1,031,250 shares of Common Stock issuable in the aggregate upon exercise of the Issuer warrants held by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP, plus (iv) 350,000 shares of Common Stock issuable in the aggregate upon draws of the Issuer under the Conversant Equity Commitment entered into by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP.


    CUSIP NO. 140475203
    1
    NAMES OF REPORTING PERSONS
     
     
    Conversant Private GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    1,438,263(1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    1,438,263(1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,438,263(1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    6.6%(2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1) Consists of 1,438,263 shares of Common Stock.
    (2) The percentage reflected is based on the sum of (i) 19,070,277 outstanding shares of Common Stock on September 13, 2024, as provided under Form S-3 filed by the Issuer with the Commission on September 27, 2024, plus (ii) 1,281,205 shares of Common Stock issuable in the aggregate upon conversion of the Series A Preferred Stock held by Conversant Dallas Parkway (A) L.P. and Conversant Dallas Parkway (B) LP, plus (iii) 1,031,250 shares of Common Stock issuable in the aggregate upon exercise of the Issuer warrants held by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP, plus (iv) 350,000 shares of Common Stock issuable in the aggregate upon draws of the Issuer under the Conversant Equity Commitment entered into by Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP.



     
    This Amendment No. 6 (“Amendment No. 6”) further amends and supplements the original statement on Schedule 13D filed by Conversant Dallas Parkway (A), L.P. (“Investor A”), Conversant Dallas Parkway (B), L.P. (“Investor B”), Conversant GP Holdings LLC (“Conversant GP”), Conversant Capital LLC (“Conversant Capital”), and Michael J. Simanovsky on November 12, 2021 (the “Original Schedule 13D”), as previously amended by them by the amended statement on Schedule 13D filed on August 21, 2024 (“Amendment No. 5”), Amendment No. 4 on March 26, 2024 (“Amendment No. 4”), Amendment No. 3 filed on February 6, 2024 (“Amendment No. 3”), Amendment No. 2 filed on November 6, 2023 (“Amendment No. 2”) and Amendment No. 1 filed on July 7, 2023 (“Amendment No. 1”). Amendment No. 4 was the initial statement on Schedule D for Conversant Dallas Parkway (D), L.P. (“Investor D”) regarding the Issuer. Amendment No. 5 was the initial statement on Schedule D for Conversant PIF Aggregator A L.P. (“Aggregator A”) and Conversant Private GP LLC (“Conversant Private GP”) regarding the Issuer. To the extent applicable, the Original Schedule 13D, as previously and hereby amended, is hereby adopted by Conversant Dallas Parkway (F), L.P. (“Investor F”) as its original filing on Schedule 13D regarding the Issuer. Investor A, Investor B, Investor D, Aggregator A and Investor F together are the “Conversant Investors,” and they, together with Conversant GP, Conversant Capital, Conversant Private GP and Mr. Simanovsky are, the “Reporting Persons.” The Original Schedule 13D, as previously amended, remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 6, provided that with respect to any Item amended herein, if such Item is incorporated by reference into any other Item in the Original Schedule 13D, as previously amended, such incorporation by reference is also amended hereby. Capitalized terms used and not defined in this Amendment No. 6 have the meanings set forth in the Original Schedule 13D, as previously amended.
     

     Item 2.
     Identity and Background
     

    Item 2 is hereby amended and restated to read as follows:
        
         (a), (f) This Schedule 13D is being filed pursuant to Rule 13d-1(a) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by:
         
       i.
    Conversant Dallas Parkway (A), L.P., a Delaware limited partnership (“Investor A”);
       ii.
    Conversant Dallas Parkway (B), L.P., a Delaware limited partnership (“Investor B”);
       iii.
    Conversant Dallas Parkway (D), L.P., a Delaware limited partnership (“Investor D”);
       iv.
    Conversant PIF Aggregator A L.P., a Delaware limited partnership (“Aggregator A”);
       v.
    Conversant Dallas Parkway (F), L.P., a Delaware limited partnership (“Investor F” and together with Investor A, Investor B, Investor D and Aggregator A, the “Conversant Investors”);
       vi.
    Conversant GP Holdings LLC, a Delaware limited liability company (“Conversant GP”);
       vii.
    Michael J. Simanovsky, a citizen of the United States of America;
       viii.
    Conversant Private GP LLC, a Delaware limited liability company (“Conversant Private GP”); and
       ix.
    Conversant Capital LLC, a Delaware limited liability company (“Conversant Capital” and together with the Conversant Investors, Conversant GP, Conversant Private GP and Mr. Simanovsky, the “Reporting Persons”).
        
    Investor A, Investor B, Investor D and Investor F are alternative investment vehicles of Conversant GP established for purpose of investing in Issuer’s securities. Aggregator A is an alternative investment vehicle of Conversant Private GP established for purpose of investing in Issuer’s securities. Conversant Capital is the investment manager of and makes investment decisions for the Conversant Investors. Mr. Simanovsky is the managing member of Conversant Capital. Conversant GP is the general partner of each of Investor A, Investor B, Investor D and Investor F. Conversant Private GP is the general partner of Aggregator A. Mr. Simanovsky is the managing member of Conversant GP and Conversant Private GP. By virtue of these relationships, each of Conversant Capital, Conversant GP, Conversant Private GP and Mr. Simanovsky may be deemed to beneficially own the shares of Common Stock (including Common Stock issuable upon conversion of Series A Preferred Stock or upon exercise of warrants to purchase Common Stock) owned directly by the Conversant Investors.
        
    The Reporting Persons are filing this statement jointly with respect to the same securities as contemplated by Rule 13d-1(k)(1). The Conversant Investors and Conversant Capital may constitute a “group” within the meaning of Section 13(d)(3) of the Exchange Act and Rule 13d-5(b) promulgated by the Securities and Exchange Commission (the “Commission”) thereunder. Each of the Conversant Investors expressly disclaims beneficial ownership of the shares of Common Stock owned and held by the other Reporting Persons.
        





    (b) The address of the principal business office of each of the Reporting Persons is: c/o Conversant Capital LLC, 25 Deforest Avenue, Summit, NJ 07901.
     
    (c) The principal business of Mr. Simanovsky is investment management. Investor A, Investor B, Investor D, Investor F and Aggregator A are each private investment vehicles. Conversant GP is the general partner of Investor A, Investor B, Investor D and Investor F and Conversant Private GP is the general partner of Aggregator A. Conversant Capital is the investment manager to the Conversant Investors.  

        (d)-(e) During the last five years, none of the Reporting Persons has: (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    Item 3.
    Source and Amount of Funds or Other Consideration

    Item 3 is hereby amended by the addition of the following:


    On October 10, 2024, for no consideration, Conversant GP caused Investor B to distribute 648,942 shares of Common Stock to an investor, who in turn deposited them with Investor F.

    Further, the disclosure set forth below in Item 5(c) below regarding open market purchases of shares of Common Stock by Aggregator A  is incorporated herein. The open market purchases by Aggregator A were made using existing investment capital.

    Item 4.
    Purpose of Transaction

    Item 4 is hereby amended by the addition of the following:

        The disclosure set forth above in Item 3 above regarding the transfer of shares of Common Stock to Investor F is incorporated herein.

    Item 5.
    Interest in Securities of the Issuer.

       
    Items 5(a) and (b) are hereby amended and restated to read as follows:
         
     (a), (b) For information regarding beneficial ownership, see the information presented on the cover pages of this Schedule 13D.
         
    Item 5(c) is hereby amended by the addition of the following:
         
    (c) Other than as described in Item 3 above and certain open market purchases by Aggregator A, namely, (i) 9,564 shares of Common Stock for a $22.96 per share price for a total of $219,875.40 purchased on October 14, 2024; (ii) 15,927 shares of Common Stock for a $23.95 per share price for a total of $381,851.42 purchased on October 15, 2024 and (iii) 8,957 shares of Common Stock for a $25.46 per share price for a total of $228,302.29 purchased on October 16, 2024, the Reporting Persons have not engaged in any transactions in the Common Stock since the date of Amendment No. 5.

    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Item 6 is hereby amended by the addition of the following:

     

         The disclosure set forth above in Item 3 above regarding the transfer of shares of Common Stock to Investor F is incorporated herein.

    Item 7.
    Material to be Filed as Exhibits

    Item 7 is hereby amended by the replacement of Exhibit 99.1.









    99.1
    Joint Filing Agreement, dated October 17, 2024.



    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated: October 17, 2024

      CONVERSANT DALLAS PARKWAY (A) LP  
      By:  Conversant GP Holdings LLC, its general partner  
           

    /s/ Paul Dumaine  
      Name: Paul Dumaine  
     
    Title:  General Counsel and Chief Compliance Officer
     
           
           
      CONVERSANT DALLAS PARKWAY (B) LP  
      By:  Conversant GP Holdings LLC, its general partner  
         
      /s/ Paul Dumaine  
      Name: Paul Dumaine  
     
    Title:  General Counsel and Chief Compliance Officer
     
         
         
     
    CONVERSANT DALLAS PARKWAY (D) LP
     
     
    By:  Conversant GP Holdings LLC, its general partner
     
         
      /s/ Paul Dumaine  
     
    Name:  Paul Dumaine
     
     
    Title:  General Counsel and Chief Compliance Officer
     
         
         
     
    CONVERSANT DALLAS PARKWAY (F) LP
     
      By:  Conversant GP Holdings LLC, its general partner  
         
      /s/ Paul Dumaine  
      Name: Paul Dumaine  
     
    Title: General Counsel
     
         
         
      CONVERSANT PIF AGGREGATOR A LP
     
      By:  Conversant Private GP LLC, its general partner
     
         
      /s/ Paul Dumaine  
      Name: Paul Dumaine  
     
    Title: General Counsel and Chief Compliance Officer
     
         
         
      CONVERSANT GP HOLDINGS LLC
     
         
      /s/ Paul Dumaine  
      Name: Paul Dumaine  
     
    Title:  General Counsel and Chief Compliance Officer
     
         
         
      CONVERSANT CAPITAL LLC
     
         
      /s/ Paul Dumaine
     
      Name: Paul Dumaine
     
      Title:  Attorney-in-Fact for Michael J. Simanovsky
     
         
         
      MICHAEL J. SIMANOVSKY
     
         
      /s/ Paul Dumaine
     
      Name: Paul Dumaine
     
      Title: General Counsel and Chief Compliance Officer
     
         
         
      CONVERSANT PRIVATE GP LLC
     
         
       /s/Paul Dumaine
     
      Name: Paul Dumaine
     
      Title: General Counsel and Chief Compliance Officer
     
     


    Get the next $SNDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNDA

    DatePrice TargetRatingAnalyst
    12/13/2024$25.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SNDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on Sonida Senior Living with a new price target

      Morgan Stanley initiated coverage of Sonida Senior Living with a rating of Equal-Weight and set a new price target of $25.00

      12/13/24 8:22:29 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care

    $SNDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Sonida Enhances Executive Team and Board to Support Company Growth

      Max Levy appointed Chief Investment Officer in newly created role Lilly H. Donohue, a long-time senior living industry executive, to join Board of Directors Sonida Senior Living, Inc. ("Sonida" or the "Company") (NYSE:SNDA), a leading owner-operator and investor in communities and services for seniors, today announced the appointment of Max Levy to the newly created role of Chief Investment Officer ("CIO"). In addition, the Company also announced today that Lilly H. Donohue will be appointed to the Board. As CIO and a member of the executive committee, Mr. Levy, who is transitioning to Sonida from his role as a Principal at Conversant Capital ("Conversant"), the Company's largest shar

      5/10/24 5:30:00 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Sonida Senior Living Names Tabitha Obenour Chief Clinical Officer

      Expands Sonida's Leadership Team with Robust Clinical Operations Expertise Sonida Senior Living, Inc. (the "Company" or "Sonida Senior Living") (NYSE:SNDA), a leading owner-operator of senior living communities and services, announced the appointment of Tabitha Obenour as Vice President and Chief Clinical Officer, effective November 1, 2023. Obenour joins Sonida from senior living provider Enlivant where she served as the company's Vice President of Clinical Quality and Compliance. "As our company continues to look for growth opportunities, operational excellence and resident care remain our highest priorities. A clinical leader with 20 years' experience, Tabitha has a deep understandin

      11/3/23 8:49:00 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Sonida Senior Living Announces Leadership Transition

      CEO Kim Lody to step down after eight years with the Company Brandon Ribar promoted from COO to CEO Sonida Senior Living, Inc. (the "Company" or "Sonida") (NYSE:SNDA), one of the nation's leading senior living owner-operators, announced that Kimberly S. Lody has decided to step down after an eight-year tenure with the Company, including approximately three and a half years as Chief Executive Officer (CEO). In accordance with the Company's succession plan, Brandon M. Ribar, the Company's Chief Operating Officer (COO), has been appointed President and CEO, effective September 2, 2022. Lody will continue to serve in her current role through September 2, 2022, to ensure a smooth transition. Ri

      8/4/22 5:00:00 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care

    $SNDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SNDA
    Financials

    Live finance-specific insights

    See more

    $SNDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SNDA
    SEC Filings

    See more

    $SNDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Ribar Brandon bought $98,668 worth of shares (4,000 units at $24.67), increasing direct ownership by 1% to 327,176 units (SEC Form 4)

      4 - SONIDA SENIOR LIVING, INC. (0001043000) (Issuer)

      5/23/25 9:47:19 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Director Simanovsky Michael bought $897,835 worth of shares (42,111 units at $21.32) (SEC Form 4)

      4 - SONIDA SENIOR LIVING, INC. (0001043000) (Issuer)

      1/13/25 2:06:54 PM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • President & CEO Ribar Brandon bought $90,720 worth of shares (4,000 units at $22.68), increasing direct ownership by 1% to 315,469 units (SEC Form 4)

      4 - SONIDA SENIOR LIVING, INC. (0001043000) (Issuer)

      11/19/24 4:47:54 PM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Sonida Announces First Quarter 2025 Earnings Release Date and Conference Call

      Sonida Senior Living, Inc. ("Sonida" or the "Company") (NYSE:SNDA), a leading owner, operator and investor in communities and services for seniors, today announced that it will issue its first quarter 2025 earnings results before the market opens for trading on Monday, May 12, 2025. The Company will then host a conference call and webcast to review its financial performance and operating results at 11:00 a.m. Eastern Time. The dial-in number for the conference call is (800) 715-9871 (or +1 (646) 307-1963 for international callers), and the participant passcode is 4619110. A live webcast can be accessed here. All participants are asked to register and connect 10 minutes prior to the start o

      5/2/25 8:15:00 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Sonida Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call

      Sonida Senior Living, Inc. ("Sonida" or the "Company") (NYSE:SNDA), a leading owner, operator and investor in communities and services for seniors, today announced that it will issue its fourth quarter and full year 2024 earnings results before the market opens for trading on Monday, March 17, 2025. The Company will then host a conference call and webcast to review its financial performance and operating results at 11:00 a.m. Eastern Time. The dial-in number for the conference call is (800) 715-9871 (or +1 (646) 307-1963 for international callers), and the participant passcode is 4619110. A live webcast can be accessed here. All participants are asked to register and connect 10 minutes pr

      3/3/25 8:15:00 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Sonida Announces Third Quarter 2024 Earnings Release Date and Conference Call

      Sonida Senior Living, Inc. ("Sonida" or the "Company") (NYSE:SNDA), a leading owner, operator and investor in communities and services for seniors, today announced that it will issue its third quarter 2024 earnings results before the market opens for trading on Wednesday, November 13, 2024. The Company will then host a conference call and webcast to review its financial performance and operating results at 11:00 a.m. Eastern Time. The dial-in number for the conference call is (800) 715-9871 (or +1 (646) 307-1963 for international callers), and the participant passcode is 4619110. A live webcast can be accessed here. All participants are asked to connect 10 minutes prior to the start of the

      10/29/24 5:00:00 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Sonida Senior Living Announces First Quarter 2025 Results

      Sonida Senior Living, Inc. (the "Company," "Sonida," "we," "our," or "us") (NYSE:SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2025. "Sonida's strong execution on its organic and inorganic growth strategy plan continued to bear meaningful results in the first quarter, driven by improvements in key metrics. Year-over-year same-store portfolio NOI margin expansion coupled with focused integration and accelerating sequential NOI margin growth in the acquisitions portfolio, demonstrates both the capabilities and potential of our unique owner/operator framework. The Company remains actively involved

      5/12/25 8:15:00 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Sonida Announces Participation in Upcoming Conferences

      Sonida Senior Living, Inc. ("Sonida" or the "Company") (NYSE:SNDA), a leading owner, operator and investor in senior living communities, announced today that Brandon Ribar, President & Chief Executive Officer, Kevin Detz, Chief Financial Officer and Max Levy, Chief Investment Officer, will participate in the following upcoming investor conferences: 2025 BMO North American Real Estate Conference (New York City) Sonida management will participate in one-on-one meetings with institutional investors on May 13th and 14th. 2025 RBC Capital Markets Global Healthcare Conference (New York City) Sonida management will participate in one-on-one meetings on May 20th and 21st. Brandon Ribar will pa

      5/8/25 8:15:00 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • The Wellington at North Bend Crossing Expands Assisted Living and Memory Care Services, Coming Summer 2025

      Sonida Senior Living has announced the expansion of The Wellington at North Bend Crossing with the addition of its new Vista building, further strengthening its presence in the Cincinnati area. The newly constructed, four-story building is now welcoming visitors for tours ahead of its anticipated summer 2025 opening. The Vista building will add 82 new Assisted Living and Memory Care apartments, supporting a maximum occupancy of 113 residents. Overseen by the community's trusted leadership team, the expansion will create nearly 65 new jobs in the Cincinnati area. "We're thrilled to expand our presence in Cincinnati and serve even more families with personalized care and meaningful engagemen

      5/2/25 2:34:00 PM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • SEC Form 10-Q filed by Sonida Senior Living Inc.

      10-Q - SONIDA SENIOR LIVING, INC. (0001043000) (Filer)

      5/12/25 8:43:45 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Sonida Senior Living Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SONIDA SENIOR LIVING, INC. (0001043000) (Filer)

      5/12/25 8:16:44 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • SEC Form DEF 14A filed by Sonida Senior Living Inc.

      DEF 14A - SONIDA SENIOR LIVING, INC. (0001043000) (Filer)

      4/29/25 8:01:20 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Amendment: SEC Form 4 filed by President & CEO Ribar Brandon

      4/A - SONIDA SENIOR LIVING, INC. (0001043000) (Issuer)

      5/23/25 10:55:20 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • President & CEO Ribar Brandon bought $98,668 worth of shares (4,000 units at $24.67), increasing direct ownership by 1% to 327,176 units (SEC Form 4)

      4 - SONIDA SENIOR LIVING, INC. (0001043000) (Issuer)

      5/23/25 9:47:19 AM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • EVP & Chief Financial Officer Detz Kevin was granted 14,881 shares, increasing direct ownership by 8% to 192,164 units (SEC Form 4)

      4 - SONIDA SENIOR LIVING, INC. (0001043000) (Issuer)

      5/21/25 9:14:53 PM ET
      $SNDA
      Hospital/Nursing Management
      Health Care

    $SNDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Sonida Senior Living Inc.

      SC 13D/A - SONIDA SENIOR LIVING, INC. (0001043000) (Subject)

      10/17/24 5:33:31 PM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Sonida Senior Living Inc.

      SC 13D/A - SONIDA SENIOR LIVING, INC. (0001043000) (Subject)

      8/21/24 7:18:19 PM ET
      $SNDA
      Hospital/Nursing Management
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Sonida Senior Living Inc.

      SC 13D/A - SONIDA SENIOR LIVING, INC. (0001043000) (Subject)

      8/19/24 4:26:52 PM ET
      $SNDA
      Hospital/Nursing Management
      Health Care